Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
A business making money today isn’t necessarily a winner, which is why we analyze companies across multiple dimensions at StockStory. That said, here is one profitable company that balances growth and profitability and two that may face some trouble.
Two stocks to sell:
ESAB (ESAB)
Trailing 12-month GAAP operating margin: 12.1%
Having played a significant role in the construction of the iconic Sydney Opera House, ESAB (NYSE: ESAB) manufactures and sells welding and cutting equipment for numerous industries.
Why Are We Hesitant About ESAB?
- 4.2% annual revenue growth over the last two years was slower than its industrials peers
- Organic sales performance over the past two years indicates the company may need to make strategic adjustments or rely on M&A to catalyze faster growth
- Shrinking returns on capital suggest that increasing competition is eating into the company’s profitability
ESAB’s stock price of $71.47 implies a valuation ratio of 12.7x forward P/E. Read our free research report to see why you should think twice about including ESAB in your portfolio.
LifeStance Health Group (LFST)
Trailing 12-month GAAP operating margin: 4.9%
With over 6,600 licensed mental health professionals treating more than 880,000 patients annually, LifeStance Health (NASDAQ: LFST) provides outpatient mental health services through a network of clinicians offering psychiatric evaluations, psychological testing, and therapy across 33 states.
Why Does LFST Worry Us?
- Revenue base of $1.58 billion puts it at a disadvantage compared to larger competitors exhibiting economies of scale
- Lacking free cash flow generation means it has few chances to reinvest for growth, repurchase shares, or distribute capital
- Push for growth has led to negative returns on capital, signaling value destruction
LifeStance Health Group is trading at $13.43 per share, or 35.9x forward P/E. To fully understand why you should be careful with LFST, check out our full research report (it’s free).
One stock to watch:
Nova (NVMI)
Trailing 12-month GAAP operating margin: 29%
Headquartered in Israel, Nova (NASDAQ: NVMI) is a provider of quality control systems used in semiconductor manufacturing.
Why Does NVMI Stand Out?
- Impressive 23.4% annual revenue growth over the last five years indicates it’s winning market share this cycle
- Healthy operating margin of 29% shows it’s a well-run company with efficient processes, and its operating leverage amplified its profits over the last five years
- Earnings per share grew by 27.4% annually over the last five years and trumped its peers
At $312.42 per share, Nova trades at 26.9x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free.
Stocks we like even more
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.
